LongBio, a biopharmaceutical company specializing in biomacromolecule drug development and based in Suzhou, China, has reportedly secured nearly RMB 100 million in a Series B2 financing round. The round was led by Qiming Venture Partners, with the funds earmarked to accelerate the clinical trials of its core programs in China, as well as to bolster product marketing and strategic global market expansion.
The company is on track to complete Investigational New Drug (IND) applications for LP-003 and LP-005 in the US. LP-003, a next-generation anti-IgE antibody, has demonstrated remarkable efficacy and safety in a Phase II study for allergic rhinitis, showing the potential to be a best-in-class therapy. Its Phase III study is currently underway, with plans for a marketing filing anticipated in the second half of 2025. Additionally, LP-005, a first-in-class complement bifunctional antibody, is slated for a Phase II study in Paroxysmal Nocturnal Hemoglobinuria (PNH).- Flcube.com
